ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1160

Mapping Spondyloarthritis Susceptibility Loci in B10.RIII Mice

Jyotsna Soundararajan1, Anu Shivalikanjli2, Thomas Keane2 and Joerg Ermann3, 1Brigham and Women's Hospital, Boston, MA, 2European Molecular Biology Laboratory, European Bioinformatics Institute, Cambridge, United Kingdom, 3Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Meeting: ACR Convergence 2022

Keywords: genetics, Mouse Models, Other, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Spondyloarthritis Including PsA – Basic Science Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Overexpression of IL-23 using IL-23 minicircle DNA in B10.RIII mice results in the development of a spondyloarthritis-like disease. B10.RIII (B10.RIII-H2r H2-T18b/(71NS)SnJ) is a major histocompatibility complex (H-2) congenic strain derived from a cross between the donor strain RIII/WySn (RIII, H-2r) and the background strain C57BL/10Sn (B10, H-2b), followed by seven backcrosses to the background strain. In contrast to B10.RIII mice, B10 mice do not develop IL-23 minicircle-induced arthritis. This difference in phenotype is accounted for by the differences in the genetic backgrounds of the two strains. We set out to identify genomic regions determining arthritis susceptibility in this model.

Methods: The genome sequences of B10.RIII and B10 mice (B10.RIII(71NS)/Sn, C57BL/10SnJ, C57BL/10J) were compared using data from the European Variation Archive. Subcongenic mice were generated replacing individual RIII-derived regions in the B10.RIII genome (r allele) with the B10 interval (b allele). Adult male mice were hydrodynamically injected with 50 ng IL-23 EEV (System Biosciences), and arthritis development was monitored every other day for two weeks. Splenocytes from B10.RIII and B10 mice were sorted into 8 immune cell subsets and analyzed by bulk RNA-seq.

Results: Genome sequence analysis of B10.RIII and B10 strains confirmed RIII-derived regions in the B10.RIII chromosomes 10 (52 Mbp, previously reported) and 17 (25 Mbp, containing the congenic H-2r region). In addition, a small telomeric region on chromosome 14 (5 Mbp) and a large region on chromosome 15 (57 Mbp) were identified as RIII-derived. The RIII-derived regions in B10.RIII contain variants predicted to be damaging to the gene function and these variants are absent in the parental B10 strains. The RIII-derived region on chromosome 15 overlaps with arthritis QTLs previously identified in other models (Figure 1). Experiments with subcongenic strains showed that the RIII-derived regions on chromosomes 15 and 17 but not the chromosome 10 region affect susceptibility to IL-23 minicircle-induced arthritis in an autosomal dominant fashion (Figure 2). RIII-derived clusters accounted for a higher proportion of the differentially expressed genes in immune cell subsets from B10.RIII and B10 mice. Several genes carrying damaging variants were differentially expressed. We integrated genome sequence variation and gene expression data with information on gene function, arthritis QTLs, and arthritis-associated genes in humans to identify candidate genes for further analysis.

Conclusion: Susceptibility of B10.RIII mice to IL-23 induced spondyloarthritis-like disease is controlled by two major RIII-derived genomic regions, the congenic H-2r on chromosome 17 and a “contaminating” region on chromosome 15 that overlaps with arthritis susceptibility loci previously identified in other models. Candidate susceptibility genes include the Ly6 cluster on chromosome 15 and Ilrun on chromosome 17.

Supporting image 1

Partial map of chromosome 15 showing the overlap between previously identified arthritis QTLs and the RIII-derived region (blue) in the B10.RIII genome. The position of microsatellite markers used for genotyping is shown in Mbp. Eae = experimental autoimmune encephalomyelitis, Cia = collagen-induced arthritis, Pgia = proteoglycan-induced arthritis

Supporting image 2

Subcongenic B10.RIII mice heterozygous b/r for the chromosome 15 region (Chr15br) were intercrossed to generate littermates that were Chr15bb, Chr15br or Chr15rr. 8_12-week-old male mice received 50 ng IL_23 EEV via hydrodynamic tail vein injection on day 0. Animals were monitored for clinical score and paw swelling every 2 days until day 14. Data are mean ± SD with 5-7 mice per group.


Disclosures: J. Soundararajan, None; A. Shivalikanjli, None; T. Keane, None; J. Ermann, Novartis, Pfizer, AbbVie/Abbott, UCB, Eli Lilly.

To cite this abstract in AMA style:

Soundararajan J, Shivalikanjli A, Keane T, Ermann J. Mapping Spondyloarthritis Susceptibility Loci in B10.RIII Mice [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/mapping-spondyloarthritis-susceptibility-loci-in-b10-riii-mice/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mapping-spondyloarthritis-susceptibility-loci-in-b10-riii-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology